Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vasopressin + nitroglycerin
- Development stage
- Preclinical
- Lead developer
- Par Health
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Vasopressin + nitroglycerin is a drug combination used primarily in cardiovascular emergencies. This combination leverages the complementary effects of both medications to optimize hemodynamic parameters. Vasopressin is a hormone that causes vasoconstriction, while nitroglycerin is a vasodilator. When used together, nitroglycerin helps counteract some of the adverse systemic effects of vasopressin while maintaining or enhancing its therapeutic benefits. The combination has been studied for use in cardiopulmonary resuscitation (CPR), management of portal hypertension in cirrhotic patients, and other cardiovascular conditions. Studies have shown that adding nitroglycerin to vasopressin can reduce portal venous resistance, further decrease portal pressure, and reverse the detrimental systemic hemodynamic effects of vasopressin while preserving its beneficial effects.
- Other names
- EVNvasopressin plus nitroglycerin
02
Targets
AVPR1A (Arginine vasopressin receptor 1A)sGC (Soluble Guanylyl Cyclase)AVPR2 (Arginine vasopressin V2 receptor)ALDH2 (Mitochondrial Aldehyde Dehydrogenase)
Beyond the preview
Go deeper on vasopressin + nitroglycerin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vasopressin + nitroglycerin.